In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Business As Usual Is Not A Vision For The Future – The Value-Based Shift Is Underway

Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.

Healthcare Systems Reimbursement Market Access

Pharma Sourcing And Procurement: The New Strategy Of Spend

Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise? In Vivo talks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

Business Strategies Growth BioPharmaceutical

Billion Dollar Bets, Health Care Magic

Investments of over $100 million are now close to becoming the predominant class of venture capital deployed in the life sciences. What is behind this shift in venture investing and how might it impact companies' strategy to attract the big bucks.

Financing Market Intelligence BioPharmaceutical

State Of Pharma R&D: Ex-Takeda’s Yamada Takes The Long View

Industry veteran Tadataka Yamada draws on his multidisciplinary background for perspectives on what’s new – and what isn’t – in a field where every researcher has at some point experienced the same teachable moment:  when you strive to make a medicine, so many things can go wrong.

Research & Development Clinical Trials Leadership

2018 Outlook

Insights from In Vivo on what to expect in the coming year

Recent Tweets from In Vivo

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

2017 Completed Trials: Status Quo Or No?

Trialtrove data provides window onto the landscape of industry-sponsored clinical trials completed during 2017.

Clinical Trials Research & Development

Procurement In Practice: For Roivant Sciences, Speed Is The VANTage Point

Roivant has a unique business model of a connected family of operationally independent companies – known as “Vants” – each with a mission to develop and commercialize new therapies for patients with unmet medical needs. In an interview with Roivant's Kris Ungvarsky, In Vivo takes a closer look at how this affect sourcing and procurement.

Business Strategies Growth

How Healthy Is Your Growth Strategy? Five Principles To Fight Complexity In Today’s Medtech And Biopharma Enterprise

Top performers in today’s health care market are transforming their growth strategies. They excel at category leadership, cost reduction and customer-focused innovation. Complexity – in strategy, portfolios, operations, organizations and people – is a little-noticed impediment to achieving margin-busting growth, on target and on time.

Business Strategies Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

The quality of clinical trials and data analysis have come a long way in the past 10 years – and even in the past three, says Christian Hebenstreit of Medidata, the cloud-based platform that supports pharma and medtech companies through clinical studies ahead of their commercial uptake. The buzzwords of the fairly recent past are now being applied as real tools in the clinical trials arena, and look set to transform the sector.

Clinical Trials Innovation

European Medtech SMEs Are In Denial Over EU MDR And New Clinical Data Needs

The EU Medical Device Regulation (MDR) is front and center for global medtech companies wanting to succeed in the EU in the next decade and beyond. Or at least it should be, but the fear is that smaller players are not ready for its stringent clinical trials regulations and many other key changes it will bring. The potential impact on the medtech ecosystem and the flow of innovation in Europe is becoming a serious concern.

EU Clinical Trials

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Regenerative Medicine Research & Development

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Pfizer’s Reference Point on Trial Innovation: Ask the Patient

Pfizer, an early leader in putting patients forward in the conduct of clinical trials, is continuing to test ways to move beyond process improvements to more ambitious initiatives at the front end of technology innovation.

Clinical Trials Research & Development

Execs On The Move, April 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

MedTech Europe's Brexit Challenge: Don't Forget The Kid In The EU Divorce

 The UK continues to press for favorable trading and regulatory conditions with the EU in its Brexit planning. But EU negotiators seem likely to play it by the book, with no favors shown. The medtech industry watched as the EU withdrawal agreement was approved by the EU27 at the March 2018 Euro Summit. Some weeks prior to that, MedTech Europe chief executive Serge Bernasconi told In Vivo of his fears for EU medtech if the industry was too slow in preparing for UK withdrawal. 

EU Brexit

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat

The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.


Market Access Digital Health

Doubling Pharma Value With Data Science

A once-in-a-generation opportunity has opened to digitally redesign a core part of the biopharma business. Capturing the opportunity requires vision and leadership; it’s not about the technology.

Digital Health Business Strategies

The Tailor Will See You Now – J&J's EMEA VP Explains Total Care Partnership For Hospital Systems

Johnson & Johnson's global CareAdvantage system, a tool to help hospital systems deliver quality care efficiently and affordably, was launched in spring 2017. Almost a year into the initiative, Hugo Breda, the group’s EMEA vice president, explains the role that J&J plays as it brings its unique care provision concept to clients.

Business Strategies Market Access

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Transitions In The Trial Landscape: What Will Drive RCTs Into The Clinic?

Clinical trial execution is both a curse and a promise in the heated stakes for first-mover advantage in new drug development.  It’s a curse because siloed practices and legacy behaviors die hard – and it’s a promise because the volume of diverse data and a growing push for integration are finally closing the gap between research, evidence and the patient experience with disease.   New research from the Tufts University Center for the Study of Drug Development examines the struggle between these two forces and concludes that real change in the conduct of clinical trials is beginning to take root. 

Clinical Trials Research & Development

Deals In Depth: March 2018

Merck & Co and Eisai expanded upon a 2015 trial collaboration and signed a $5.8 billion alliance. Vertical integration in the health care services industry continued with Cigna's $67 billion acquisition of PBM Express Scripts. Siemens Healthineers' $5.2 billion IPO propelled device financing to $6bn.
Deals Market Intelligence

Deals Shaping The Medical Industry, May 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2018.

Deals Market Intelligence